Abstract:
By activating ERRs, SLU‑PP‑332 binds to ERRs that turn on a PGC‑1α–linked endurance program. This program creates more mitochondria, shifts to fat as primary fuel, and increases exercise capacity in mice.
Step‑by‑step mechanism
-
Direct receptor activation: SLU‑PP‑332 binds ERRs (non‑selectively across α/β/γ), with multiple lines of evidence showing functional ERRα dependence for the exercise phenotype.
-
Coactivator recruitment: Activated ERRs recruit PGC‑1α (the “master regulator of mitochondrial biogenesis”—making more energy factories).
-
Gene program engagement: SLU‑PP‑332 induces an acute aerobic exercise gene signature in skeletal muscle, including Pdk4. Pdk4 (pyruvate dehydrogenase kinase 4) is an enzyme that down‑shifts carbohydrate burning to favor fat while inhibiting the gatekeeping enzyme that channels glucose into mitochondria.
-
Cellular remodeling. Studies show increased oxidative type IIa fibers (fatigue‑resistant muscle), higher mitochondrial content, and stronger expression of respiratory chain components.
Checkpoint
- Respiratory exchange ratio (RER): a breath‑level metric where lower RER means more fat is being used as fuel.
- Fatty acid oxidation: “fat burning” inside mitochondria.
What the animal data actually show
-
Fuel shift & energy use: Within ~2 hours of dosing, mice show a lower RER (more fat burning), sustained over days; fatty acid oxidation rises and energy expenditure increases without more activity or food intake.
-
Body composition on high‑fat diet: Over 28 days at 50 mg/kg i.p. twice daily, diet‑induced obese mice lost ~12% body weight vs baseline and accumulated ~10× less fat mass than controls, with no loss of lean mass. The lean mass preservation matters because weight loss that sacrifices muscle undermines metabolic health.
-
Glycemic readouts: In high‑fat diet models, glucose tolerance improved; in chow‑fed mice, fasting/fed glucose and insulin were largely unchanged—highlighting context‑dependent effects.
-
Endurance: In independent work, SLU‑PP‑332 increased endurance performance in healthy mice—reports include ~70% longer time to exhaustion and ~45% farther distance after short‑course dosing.
Clinical takeaway (early‑stage):
The mechanism aligns tightly with what endurance training does—but all efficacy data so far are preclinical. Human pharmacokinetics, durability, and inter‑individual variability remain unknown.
Works cited
https://pmc.ncbi.nlm.nih.gov/articles/PMC11584170/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/
https://news.ufl.edu/2023/09/exercise-mimicking-drug/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10215733/
Part 1: https://alphaomegapeptide.com/exercise-mimetics-101-why-errs-matter-for-metabolic-health/
“For education only; not medical advice; SLU‑PP‑332 is an investigational research compound with no human approval.”